Institute for Medical Research and Education, University Clinic, Essen, Germany.
J Steroid Biochem Mol Biol. 2014 Jul;142:48-51. doi: 10.1016/j.jsbmb.2013.12.003. Epub 2013 Dec 12.
After a worldwide breakdown of hormone therapy [HT] following the publications of the Women's Health Initiative trial and Million Women's Study in 2002-2003, there is now a trend to turn attention again to HT and to explore particular progestogens, which have been discredited with respect to their side effects. The progestogens to be considered should control undue proliferation of the endometrium and should not interfere negatively with the positive effects of estradiol, regarding carbohydrate and lipid metabolism as well as hemostasis. In the present review, three "newer progestogens" are scrutinized regarding their various actions, in combination with estradiol; the progestogens include dienogest, drospirenone and nomegestrol acetate. This article is part of a special issue entitled Menopause.
2002-2003 年，妇女健康倡议试验和百万妇女研究的出版物发表后，全球范围内的激素治疗 [HT] 崩溃，现在又出现了重新关注 HT 并探索特定孕激素的趋势，这些孕激素因其副作用而受到质疑。需要考虑的孕激素应该控制子宫内膜的过度增殖，并且不应在碳水化合物和脂质代谢以及止血方面对雌二醇的积极作用产生负面影响。在本综述中，我们仔细研究了三种“新型孕激素”与雌二醇联合使用时的各种作用；这些孕激素包括地诺孕素、屈螺酮和屈螺酮醋酸酯。本文是题为“绝经期”的特刊的一部分。
